At Bioprofarma Bagó, we are excited to present the launch of the product DALCARA® sorafenib, for our Oncology Business Unit.

DALCARA® sorafenib is approved by ANMAT for:
– the treatment of liver cancer (hepatocellular carcinoma);
– the treatment of advanced stage renal cancer (advanced renal cell carcinoma) when standard treatment has not helped to stop the disease or is not considered appropriate; and
– treatment of thyroid cancer (differentiated thyroid carcinoma).

How supplied:
DALCARA® 200 mg x 112 coated tablets.

DALCARA® sorafenib joins our portfolio of products for the treatment of kidney cancer, together with BIALKO® pazopanib and BIOZANIB® cabozantinib.

This new treatment alternative comes to provide specialists with more options for their patients’ care.